Skip to main content
Menu

Posts tagged with "Business and Markets"

  • Business and Markets

    China’s First Homegrown Pharma

    The Wall Street Journal had an article on a new HDAC inhibitor from Shenzhen Chipscreen (full text here from The Australian). It’s worth highlighting. Epidaza (chidamide) appears to be the first homegrown drug discovery and development effort to reach regulatory approval in China. Their founder, Xian-Ping Lu, was working at Galderma before he… Read More
  • Academia (vs. Industry)

    Advice for Academic Entrepreneurs

    Since I’ve mentioned a recent book on academic drug discovery, I also wanted to highlight this article at Nature Biotechnology on university tech transfer offices (TTOs). The authors, mostly from a list of high-profile research universities (Oxford, Stanford, UCSF, University College London, Harvard et al.) and part of the Oxbridge Biotech Ro… Read More
  • Biological News

    A Couple of Ycombinator’s Startups

    Last year I mentioned reports that the startup incubator Ycombinator was thinking of getting into the biopharma field. Here’s a look at the current crop of potential companies. One thing that stands out is that most of these seem to be focused on patient care or some sort of diagnostic. One exception is 20n, which… Read More
  • Business and Markets

    Nice Patent You Have There. . .

    This does not seem to me like a great advance in intellectual property law: this Bloomberg article says that some large investors are using the patent challenge process for their own purposes: Taking advantage of new rules created by Congress three years ago, hedge funds have increasingly been filing challenges to pharmaceutical patents. Some may… Read More
  • Business and Markets

    Biogen Does Not Slack Off, Apparently

    John Caroll at FierceBiotech has more on those Biogen Idec cuts last week. It was only about 20 people in chemistry and neurology – although if you were one of the ones affected, you may well ask (to quote Austrian writer Peter Altenberg) “What’s so only?” There were also cuts of about the same size… Read More
  • Business and Markets

    Biogen Layoffs

    Unfortunately, I have it from people who are definitely in a position to know that Biogen is laying off scientists this afternoon. A number of experienced chemists have been let go so far, and I’ll put up more details as I learn them. This is particularly unexpected, considering that the company appears to be in… Read More
  • Business and Markets

    The Business End and the Science End

    Enough depression for now. The last couple of posts have not been cheerful, because there’s a lot of not-so-cheerful stuff out there in the business side of the industry. But I wanted to remind everyone (and myself) that we’re actually getting some good things done around here. Take a look at oncology – it’s starting… Read More
  • Business and Markets

    Onyx Site Closed Down

    Let’s get the bad news out of the way first. Amgen’s purchase of Onyx now has the widely expected sequel: they’re closing down that site, and laying off 300 people. Kyprolis is working out fine, and that’s all Amgen wanted. The only surprise, sadly, is that it took them this long. Read More
  • Business and Markets

    The New, Nasty, Normal

    This is not a happy column by John Carroll at FierceBiotech. But it’s an accurate one. He references the period just a few years ago when Pfizer closed its Sandwich site in the UK and Roche closed Nutley, NJ, among other upheavals. That period of intense Big Pharma turmoil, though, has failed to create a… Read More
  • Business and Markets

    Shire Layoffs Soon?

    This isn’t sounding so good, either. Shire is moving its Pennsylvania site, relocating people to the main campus in Lexington, Massachusetts, but now it appears that quite a few of them won’t be making the trip: The biotech filed a WARN letter with the state of Pennsylvania outlining plans to downsize its operations at its… Read More
...212223...